Ascentage Pharma Group International (AAPG)

AAPG Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	390.6	980.65	221.98	209.71	27.91	12.45
Revenue Growth (YoY)	-56.75%	341.77%	5.85%	651.38%	124.18%	-14.21%
Cost of Revenue	35.68	29.09	30.54	22	3.33	1.97
Gross Profit	354.93	951.57	191.44	187.71	24.58	10.48
Selling, General & Admin	443.97	383.12	376.46	328.02	191.26	130.34
Research & Development	1,032	947.25	706.97	743.1	766.49	564.57
Operating Expenses	1,476	1,330	1,083	1,071	957.75	694.91
Operating Income	-1,121	-378.8	-891.99	-883.41	-933.17	-684.43
Interest Expense	-58.18	-64.46	-96.06	-52.79	-16.73	-6.26
Interest & Investment Income	59.9	37.84	32.41	9.73	7.11	5.22
Earnings From Equity Investments	0.97	-0.28	1.08	-0.28	-	-
Currency Exchange Gain (Loss)	6.69	6.69	1.62	-2.64	9.91	17.09
Other Non Operating Income (Expenses)	-31.18	4.63	20.78	49.91	139.47	19
EBT Excluding Unusual Items	-1,143	-394.37	-932.17	-879.48	-793.41	-649.38
Gain (Loss) on Sale of Investments	-0.85	-0.83	-0.7	-9.77	-20.89	-3.75
Gain (Loss) on Sale of Assets	-0.05	-0.05	0	2.07	-0.03	-
Other Unusual Items	-	-	-	-	-17.92	-22.33
Pretax Income	-1,143	-395.26	-932.86	-887.17	-832.25	-675.45
Income Tax Expense	15.87	10.43	-7.15	-4.25	-49.83	2.16
Earnings From Continuing Operations	-1,159	-405.68	-925.71	-882.92	-782.42	-677.61
Minority Interest in Earnings	0.13	0.25	0.08	-	-	-
Net Income	-1,159	-405.43	-925.64	-882.92	-782.42	-677.61
Net Income to Common	-1,159	-405.43	-925.64	-882.92	-782.42	-677.61
Shares Outstanding (Basic)	327	302	282	264	255	216
Shares Outstanding (Diluted)	327	302	282	264	255	216
Shares Change (YoY)	12.40%	7.00%	7.07%	3.56%	17.93%	84.97%
EPS (Basic)	-3.55	-1.34	-3.28	-3.35	-3.07	-3.14
EPS (Diluted)	-3.55	-1.34	-3.28	-3.35	-3.07	-3.14
Free Cash Flow	-	-135.65	-772.19	-857.2	-1,040	-859.88
Free Cash Flow Per Share	-	-0.45	-2.73	-3.25	-4.08	-3.98
Gross Margin	90.87%	97.03%	86.24%	89.51%	88.08%	84.21%
Operating Margin	-286.93%	-38.63%	-401.83%	-421.25%	-3343.50%	-5497.42%
Profit Margin	-296.77%	-41.34%	-416.98%	-421.02%	-2803.38%	-5442.62%
Free Cash Flow Margin	-	-13.83%	-347.86%	-408.75%	-3726.60%	-6906.64%
EBITDA	-1,042	-298.87	-812.82	-835.99	-915.99	-667.46
EBITDA Margin	-266.89%	-30.48%	-	-	-	-
D&A For EBITDA	78.3	79.94	79.17	47.42	17.18	16.97
EBIT	-1,121	-378.8	-891.99	-883.41	-933.17	-684.43
EBIT Margin	-286.93%	-38.63%	-	-	-	-

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q